Radiation therapy

Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of DecisionDx®-SCC in Patients with Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy

Retrieved on: 
Tuesday, October 3, 2023
Oncology, Health, Genetics, Radiology, Pharmaceutical, Biotechnology, SCC, Medical University of South Carolina, T2A, Head, ASTRO, MFS, ART, Medical school, Radiation therapy, Patient, Risk, Annual general meeting, American Society for Radiation Oncology, BWH, Society, Metastasis, Medical imaging, Brigham

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data demonstrating the ability of its DecisionDx®-SCC test to identify node-negative cutaneous squamous cell carcinoma (SCC) patients at a higher risk of metastasis who may benefit from adjuvant radiation therapy (ART).

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data demonstrating the ability of its DecisionDx®-SCC test to identify node-negative cutaneous squamous cell carcinoma (SCC) patients at a higher risk of metastasis who may benefit from adjuvant radiation therapy (ART).
  • The data will be shared in an oral presentation during the American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting, being held Oct. 1-4 in San Diego.
  • “When a patient’s risk of metastasis is unclear, tough decisions as to which treatment approaches to pursue become that much more difficult.
  • An intermediate risk population in which ART is often considered was defined as Brigham and Women’s Hospital (BWH) stage T2a or higher (n=489).

GT Medical Technologies, Inc. Presents New Data Further Demonstrating High Local Control for the Treatment of Recurrent Brain Metastases at the ASTRO 2023 Annual Meeting

Retrieved on: 
Monday, October 2, 2023
San Diego Convention Center, Brain, Radiation, Q&A, American Society for Radiation Oncology, ASTRO, Booth, Radiation therapy, Barrow Neurological Institute, Incidence, Publication, MD, Patient, Baptist Health, Annual general meeting, Poster, FDA, Society, Safety, Medical imaging, Medical device, Brachytherapy, Radiosurgery

TEMPE, Ariz., Oct. 2, 2023 /PRNewswire/ -- GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, today announced interim findings of a multi-institutional study that demonstrates high local control for the treatment of recurrent brain metastases in patients, adding to the growing evidence of the efficacy and safety of its FDA-approved GammaTile® Therapy at the American Society for Radiation Oncology's (ASTRO) 65th Annual Meeting.

Key Points: 
  • None of the patients experienced adverse effects from the radiation treatment in follow-ups, which had a median time of four months post-surgery.
  • "This robust emerging scientific data reinforces the impact GammaTile Therapy has on local control for patients with brain metastases.
  • The poster, titled: "Surgically Targeted Radiation Therapy (STaRT) for Brain Metastases: Initial Experience from a Prospective Multi-institutional Registry" will be available on the ASTRO Annual Meeting Portal .
  • The results showed that GammaTile for operable recurrent brain metastases was associated with superior local control compared to the first course of external beam radiotherapy in the series.

Aviko Radiopharmaceuticals and Neutron Therapeutics Form Exclusive, Strategic Partnership with Leo Cancer Care to Expand Development of Boron Neutron Capture Therapy for Treating Cancer

Retrieved on: 
Monday, October 2, 2023
Oncology, Health, Medical Devices, General Health, Radiology, Pharmaceutical, Biotechnology, Neutron, Partnership, ASTRO, Radiopharmaceutical, Cancer, Multimedia, Void coefficient, Radiation therapy, Patient, Physician, BNCT, Annual general meeting, Neoplasm, FDA, Therapy, Society, Pharmaceutical industry, Medical imaging

Aviko Radiopharmaceuticals , a Deerfield Management-founded biotechnology company developing medicines to unlock the potential of boron neutron capture therapy (BNCT), and Neutron Therapeutics , a leading developer of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced an exclusive, strategic partnership with Leo Cancer Care , a company developing upright patient positioning systems for radiation therapy.

Key Points: 
  • Aviko Radiopharmaceuticals , a Deerfield Management-founded biotechnology company developing medicines to unlock the potential of boron neutron capture therapy (BNCT), and Neutron Therapeutics , a leading developer of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced an exclusive, strategic partnership with Leo Cancer Care , a company developing upright patient positioning systems for radiation therapy.
  • The goal of the partnership between the three companies is to expand BNCT as a potential treatment for different types of cancer.
  • Positioning the patient in relation to the neutron beam is important to support patient safety and the clinical activity of BNCT.
  • We are excited to collaborate with Aviko and Neutron as we advance BNCT to potentially treat a variety of solid tumors.”
    The products being developed by Aviko Radiopharmaceuticals, Neutron Therapeutics and Leo Cancer Care are in development and are limited to investigational use.

Image-Guided Superficial Radiation Therapy Yields Superior 2-Year Recurrence Rates Compared to Mohs Micrographic Surgery, Cancer Journal Reports

Retrieved on: 
Monday, October 2, 2023
Columbia University, Contraindication, Columbia University Irving Medical Center, Cleveland Clinic, SCC, Radiation, Probability, University, Coagulopathy, Doctor of Philosophy, Skin, Anatomy, ASTRO, Mohs surgery, SRT, Skin cancer, Cancer, NMSC, MMS, BCC, Head, National Comprehensive Cancer Network, Toxicity, Research, Radiation therapy, Neck, SCCS, Medical Subject Headings, Dermatology, Incidence, Death, Patient, Treatment, University of South Florida College of Medicine, Carcinoma, American Society for Radiation Oncology, PubMed, European Society for Medical Oncology, Recurrence, Society, Medical imaging, Veterinary medicine, Dentistry, Pharmaceutical industry, Physician, Surgeon

BURR RIDGE, Ill., Oct. 2, 2023 /PRNewswire/ -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT, or IGSRT), today announced a newly published study revealing that IGSRT technology is superior to Mohs micrographic surgery (MMS). Image-Guided SRT is the most advanced nonsurgical treatment for common skin cancers. This peer-reviewed study "supports IGSRT as an effective treatment option for individuals with early stage NMSCs (nonmelanoma skin cancers)." The study is the first to directly compare two-year recurrence probabilities of Image-Guided SRT to Mohs.

Key Points: 
  • The study is the first to directly compare two-year recurrence probabilities of Image-Guided SRT to Mohs.
  • The report, entitled, "Image-guided superficial radiation therapy has superior 2-year recurrence probability to Mohs micrographic surgery," appears in the journal Clinical and Translational Radiation Oncology , which is published by the European Society for Radiotherapy & Oncology (ESTRO).
  • Medical Subject Headings were used to search PubMed for reports of 2-year recurrence probability rates of NMSCs treated by MMS.
  • The authors observe that prior to the invention of Mohs surgery, superficial radiation therapy (SRT) was a standard therapy offered by dermatologists for nonmelanoma skin cancer.

PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)

Retrieved on: 
Monday, October 2, 2023
Vaccine, DNA, Biotechnology, University, FIGO, Nucleic acid thermodynamics, PDSB, Neoplasm, ASTRO, Infection, HPV16, Cancer, SOC, Monroe Dunaway Anderson, Radiation therapy, Doctor of Philosophy, MD Anderson Cancer Center, CD8, Cervical cancer, MD, Patient, Lymph, Blood, Annual general meeting, American Society for Radiation Oncology, HPV, Chemoradiotherapy, Gynaecology, Oncology, CRT, Kinetics, Society, Human papillomavirus infection, Disease, Birth control, Medical imaging, Obstetrics

HPV is the primary cause of cervical cancer with over 99% caused by HPV infection, and cfHPV-DNA can be detected in the blood of patients with cervical cancer.

Key Points: 
  • HPV is the primary cause of cervical cancer with over 99% caused by HPV infection, and cfHPV-DNA can be detected in the blood of patients with cervical cancer.
  • HPV type 16 (HPV16) is the most prominent subtype associated with cervical cancer.
  • Longitudinal plasma samples were collected from each patient at baseline, during weeks 1, 3, and 5, and at 3-4 months after CRT.
  • “I look forward to the continued evaluation of PDS0101 in combination with standard-of-care chemoradiotherapy.”

Accuray and Limbus AI Unveil Online Adaptive Therapy Solution for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting

Retrieved on: 
Monday, October 2, 2023
SBRT, Cyberknife, SRS, CE, Radiation, Partnership, DIBH, Workflow, Alliance University (New York City), Neoplasm, ASTRO, Cancer, Radiation therapy, Sale, Limbus, Patient, Risk, Annual general meeting, Physics, Society, American Society for Radiation Oncology, Software, Medical device, Medical imaging, EU, Accuray, Ceno

The solution was unveiled, in partnership with Limbus AI, at the 2023 ASTRO (American Society for Radiation Oncology) Annual Meeting in San Diego, California, October 1-4, 2023.

Key Points: 
  • The solution was unveiled, in partnership with Limbus AI, at the 2023 ASTRO (American Society for Radiation Oncology) Annual Meeting in San Diego, California, October 1-4, 2023.
  • Accuray customers are currently able to leverage real-time adaptive therapy through the company's proprietary Synchrony® technology and offline adaptive with PreciseART® radiotherapy to account for some of the anatomical changes that occur during radiation delivery.
  • "We're very happy to be partnering with Accuray," said Dr Karl Otto, CEO of Limbus AI.
  • Embedding it into the Cenos online adaptive solution will help provide for accurate and fast contouring essential to real-world clinical implementation of adaptive treatment."

PreludeDx™ Presents Risk Assessments for DCIS Patients Using Clinicopathologic-Based Models Like RTOG 9804 and MSKCC Compared to DCISionRT®

Retrieved on: 
Monday, October 2, 2023
San Diego Convention Center, Surgeon, Impact, ASTRO, MSKCC, Woman, Virtual, Radiation therapy, Ductal carcinoma, IBR, NPV, Patient, Physician, Risk, Medicine, Annual general meeting, DCIS, RT, BCS, Society, American Society for Radiation Oncology, Medical imaging, MD

These DCISionRT High-Risk patients had high 10-year ipsilateral breast recurrence (IBR) rates and significant radiation therapy (RT) benefit.

Key Points: 
  • These DCISionRT High-Risk patients had high 10-year ipsilateral breast recurrence (IBR) rates and significant radiation therapy (RT) benefit.
  • In contrast, the corresponding DCISionRT Low-Risk patients had low 10-yr IBR rates and no significant RT benefit.
  • “Prior to DCISionRT, we relied primarily on traditional clinicopathologic factors to make treatment decisions.
  • Conversely, the study also demonstrated patients reclassified into the DCISionRT High-Risk groups had higher IBR rates without RT (20% and 12%) and significant absolute IBR rate reductions (13% and 8%) from RT.

CIVCO Radiotherapy and Qfix Launch CQ Medical Brand

Retrieved on: 
Sunday, October 1, 2023
Quotient, Technical University of Denmark Department of Mathematics, Culture, Institute of technology, Cancer, Intelligence, Blue Wolf Capital Partners, Research, History, Qfix robot kit, Radiation therapy, Philosophy, Radiation, Patient, Engineering, Empathy, Health, Pharmaceutical industry, Nursing

NEW YORK, Oct. 1, 2023 /PRNewswire/ -- CIVCO Radiotherapy and Qfix announced today the launch of a new brand, CQ Medical. This brand reflects the company's vision and global leadership in high-quality, patient-centric radiotherapy solutions and more than 80 years of combined experience.

Key Points: 
  • NEW YORK, Oct. 1, 2023 /PRNewswire/ -- CIVCO Radiotherapy and Qfix announced today the launch of a new brand, CQ Medical.
  • CQ Medical marks a pivotal transformation for CIVCO Radiotherapy and Qfix, who joined forces in October 2022.
  • The name CQ Medical is derived from the company's Care Quotient: IQ + EQ = CQ.
  • "CQ Medical has a great culture and employees who are dedicated to continuously improving the radiotherapy experience both for patients and providers," added Mr. Sutter.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Unveil Wide Range of Innovative Radiation Oncology Research at the 2023 ASTRO Annual Meeting

Retrieved on: 
Friday, September 29, 2023
KRAS, Abstract, RWJBarnabas Health, ASTRO, Survival, NCI-designated Cancer Center, Cancer, National Cancer Institute, Radiation, Breast, Research, Radiation therapy, Lung cancer, Immunotherapy, Associate, Lung, MS, PDA, MRD, Cooper University Hospital, Patient, Standard of care, Annual general meeting, Chemoradiotherapy, Rutgers Cancer Institute of New Jersey, Radio, Society, American Society for Radiation Oncology, Methionine, Medical imaging, MD

NEW BRUNSWICK, N.J., Sept. 29, 2023 /PRNewswire/ -- Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present new, novel, and expansive radiation oncology data from their clinical research program at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting, to be held in San Diego from October 1-4.  A total of 10 abstracts have been accepted, comprising clinical data and analyses that advance the understanding and use of radiation therapy in the treatment of lung, breast, pancreatic, and other cancers. Rutgers Cancer Institute and RWJBarnabas Health is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.

Key Points: 
  • Rutgers Cancer Institute and RWJBarnabas Health is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.
  • "We are excited that the physician-scientists from our health system will be presenting significant and valuable information to advance the use of radiotherapy in cancer treatment at this year's ASTRO meeting," said Bruce Haffty, MD, MS, Chair, Radiation Oncology, Associate Vice Chancellor for Cancer Programs at Rutgers Cancer Institute of New Jersey, and System Director of Radiation Oncology at RWJBarnabas Health.
  • Highlights of accepted abstracts include the following:
    Findings of an analysis to explore genetic changes in aggressive pancreatic cancer.
  • The full list of presentations at this year's ASTRO Annual Meeting follows:

NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology

Retrieved on: 
Friday, September 29, 2023
ASTRO, Cancer, NANO, Radiation therapy, Patient, HNSCC, Webcast, Congress, NBTXR3, Society, Pharmaceutical industry, Euronext

These data have also been selected for inclusion in two scientific highlight sessions for review and discussion during the congress.

Key Points: 
  • These data have also been selected for inclusion in two scientific highlight sessions for review and discussion during the congress.
  • During the call, Laurent Levy, chief executive officer, will review the Study 102 final data before taking questions from participants.
  • A live webcast of the call may be accessed by visiting the investors section of the Company’s website at www.nanobiotix.com .
  • A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website.